[Response criteria for urological cancer treatment].
出版信息
Nihon Hinyokika Gakkai Zasshi. 1992 Apr;83(4):447-72.
PMID:1593826
Abstract
摘要
相似文献
1
[Response criteria for urological cancer treatment].
Nihon Hinyokika Gakkai Zasshi. 1992 Apr;83(4):447-72.
2
The systemic therapy of urologic cancer.
Conn Med. 1980 Apr;44(4):217-24.
3
Autologous neoplastic isto-cryoprecipitates as immuno-stimulating treatment in 100 urological cancer patients.
J Exp Pathol. 1987 Summer;3(4):587-92.
4
The role of imaging in the surveillance of urologic malignancies.
Urol Clin North Am. 2006 Aug;33(3):377-96. doi: 10.1016/j.ucl.2006.03.001.
5
[Urologic tumors in old age].
Tijdschr Gerontol Geriatr. 1986 Apr;17(2):65-8.
6
[Update on the medical treatment of urologic tumors].
Bull Cancer. 2000 Jan;87(1):71-5.
7
[Urological cancer: treatment strategies].
AMB Rev Assoc Med Bras. 1983 Nov-Dec;29(11-12):199-209.
8
[Advances in urologic oncology].
Prog Urol. 1991 Feb;1(1):17-21.
9
[The urological group of the EORTC (European Organization for Research on the Treatment of Cancer), 1976-1984].
Arch Esp Urol. 1984 Dec;37 Suppl 2:713-23.
10
Genitourinary malignancy.
Cancer Chemother Biol Response Modif. 1994;15:531-54.
引用本文的文献
1
Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling.
Exp Ther Med. 2010 Nov;1(6):955-961. doi: 10.3892/etm.2010.148. Epub 2010 Sep 10.
2
A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study.
Int J Clin Oncol. 2006 Dec;11(6):434-40. doi: 10.1007/s10147-006-0596-z. Epub 2006 Dec 25.
Zotero 插件